Pasar al contenido principal

The immunity and signaling pathways of emergent pathogens to develop new therapeutic applications

JDC2023-050389-I

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprograma Subprograma Estatal de Formación
Convocatoria Juan de la Cierva
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA INSTITUT DE RECERCA SOBRE IMMUNOPATOLOGIES-CAIXA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m 6 A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Badia, Roger|||0000-0003-3982-7577
  • Riveira Muñoz, Eva|||0000-0002-6396-1162
  • García Vidal, Edurne|||0000-0003-0698-8710
  • Revilla, Lluís
  • Franco Cirera, Sandra|||0000-0003-4126-2202
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Roca, Núria
  • Ceada, Gerardo|||0000-0002-0524-4018
  • Kochanowski, Karl|||0000-0002-1884-7694
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Boreika, Rytis|||0000-0001-6720-1577
  • Bordoy, Antoni E.|||0000-0002-1165-542X
  • Soler, Laia|||0009-0000-4122-5079
  • Guil, Sonia|||0000-0002-2257-3331
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Blanco, Julià|||0000-0002-2225-0217
  • Martinez, Miguel Angel|||0000-0002-6681-4950
  • Paredes, Roger|||0000-0002-6553-691X
  • Losada, Alejandro
  • Avilés, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Ballana, Ester|||0000-0002-5215-7363
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m 6 A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m 6 A synthesis routes and are blocked by drugs targeting IGF2BP2 m 6 A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses. By deciphering the molecular fingerprint of cells treated with host-directed therapies targeting protein translation, the authors identified a rational approach to select for broad-spectrum antivirals with potential to counteract future pandemic viruses.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Highly Efficient Air Sterilization via Low-Temperature Interfacial Evaporation in Inductively Heated Superhydrophilic Ferromagnetic Filters

  • Fons, Arnau
  • Vaca, Cristina
  • Franco-Trepat, Eloi
  • Lafuente, Aritz
  • Tajada Herráiz, José Luis
  • Serrà, Albert
  • Díaz Pedroza, Jorge
  • Franco, Sandra
  • Boreika, Rytis
  • Erkizia, Itziar
  • Izquierdo-Useros, Núria
  • López-Ortega, Alberto
  • Garaio, Eneko
  • Esplandiú, María J.
  • Nogués, Josep
  • Sepúlveda, Borja
The scientific evidence supporting airborne transmission of pathogens in closed spaces highlights the inefficiency of current air circulation and filtration technologies (e.g., HEPA filters, UV, ozone, ionization) in preventing the spread of airborne pathogens. This underscores the urgent need for new air disinfection devices. Here, the first air sterilization technology is presented based on low-temperature interfacial evaporation. This novel approach integrates superhydrophilic micro/nano-structured stainless-steel filters and ultra-efficient magnetic inductive heating to enable complete evaporation of water from the contaminated aerosols and the precipitation of all the organic and inorganic residues within the filter at temperatures in the range of 60-80 °C. The technology is validated through experiments with contaminated aerosols with different active viruses, including SARS-CoV-2 and respiratory syncytial virus (RSV), demonstrating the elimination of 99.6% or more of the nebulized viruses, at filter temperatures of 60-80 °C and airflow rates of 15 L min-1. The filters also support pyrolytic self-cleaning and reuse, ensuring extended service time and minimal maintenance. This air sterilization technology represents a significant advancement over existing state-of-the-art filtering technology, offering unmatched versatility, low energy consumption, and cost-effective sterilization, without generating harmful radicals, dangerous high voltages, or high temperatures., A.F., C.V., and E.F.-T. contributed equally to this work. Ministerio de Ciencia e Innovación (MICIN) is acknowledged through Grant PDC2021-121303-I00, funded by NextGenerationEU and MICIU/AEI/10.13039/501100011033. MICIN is also acknowledged through Grants PID2021-124568NB-I00, PDI2022-138588OB-C31 and PDI2022-138588OB-C32 funded by MICIU/AEI/10.13039/501100011033. The IMB is supported by the Maria de Maeztu Centres of Excellence program Grant CEX2023-001397-M and the ICN2 is supported by the Severo Ochoa Centres of Excellence program, Grant CEX2021-001214-S, both funded by MCIU/AEI/10.13039/501100011033. ICN2 is funded by the CERCA program/Generalitat de Catalunya. The authors acknowledge the funding from 2021-SGR-00651 project by the Generalitat de Catalunya. N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/ 501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. The authors also thank the support of 2021 SGR 00452, CERCA and Fundación Dormeur. E.F.-T. is supported by JDC2023-050389-I and A.L.O. by CNS2022-135787 funded by MCIU/AEI/10.13039/ 501100011033, European Union NextGenerationEUPRTR and FSE+, With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (CEX2023-001397-M), With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or m6A protein synthesis routes

  • Molina Molina, Elisa
  • Bech-Serra, Joan Josep
  • Franco-Trepat, Eloi
  • Jarne, Ignasi
  • Perez-Zsolt, Daniel
  • Badia, Roger
  • Riveira-Muñoz, Eva
  • Garcia-Vidal, Edurne
  • Revilla, Lluís
  • Franco, Sandra
  • Tarrés Freixas, Ferran
  • Roca, Núria
  • Ceada, Gerardo
  • Kochanowski, Karl
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Boreika, Rytis
  • Bordoy, Antoni E.
  • Soler, Laia
  • Guil, Sonia
  • Carrillo, Jorge
  • Blanco, Julià
  • Martínez, Miguel Ángel
  • Paredes, Roger
  • Losada, Alejandro
  • Aviles, Pablo
  • Cuevas, Carmen
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Clotet, Bonaventura
  • Ballana, Ester
  • de la Torre, Carolina
  • Izquierdo-Useros, Nuria
Plitidepsin is an antitumoral compound safe for treating COVID-19 that targets the translation elongation factor eEF1A. Here we detect that plitidepsin decreases de novo cap-dependent translation of SARS-CoV-2 and non-viral RNAs but affects less than 13% of the host proteome, thus preserving cellular viability. In response to plitidepsin, cells upregulate EIF2AK3 and proteins that reduce translation, but also proteins that support proteostasis via ribosome synthesis and cap-independent translation by eIF4G2 and IGF2BP2. While plitidepsin inhibits cap- or internal ribosome entry sites (IRES)-mediated translation, its impact on N6-methyladenosine (m6A) translation is limited. In agreement, plitidepsin blocks members of Coronaviridae, Flaviviridae, Pneumoviridae and Herpesviridae families. Yet, it fails to inhibit retroviruses that exploit m6A synthesis routes and are blocked by drugs targeting IGF2BP2 m6A reader. By deciphering the molecular fingerprint of cells treated with therapies targeting translation we identify a rational approach to select broad-spectrum antivirals with potential to counteract future pandemic viruses., N.I-U. is supported by the Spanish Ministry of Science and Innovation (grants PID2020-117145RB-I00, PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union) and by institutional funding of PharmaMar, Grifols, HIPRA, and Amassence. E.M-M. is supported by the Spanish Ministry of Science and Innovation (grant PRE2021-099271). E.F-T is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. E.G-V. is a research fellow from PERIS (SLT017/20/000090). E.B. and R.B. are research fellows from ISCIII-FIS (CPII19/00012; CP19/00011). K.K. is supported by funding from the Spanish Ministry of Research and Innovation (RYC2021-033035-I/AEI/10.13039/501100011033). G.C. is supported with funding from PLEC2022-009171/AEI/10.13039/501100011033. IrsiCaixa is supported by 2021 SGR 0045. The proteomic analyses were conducted at the IJC Proteomics Unit, which is affiliated with the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Spanish Platform of Molecular and Bioinformatics Resources (ProteoRed), Instituto de Salud Carlos III (PT17/0019), and CERCA GINYNS. This unit serves as a gateway to scientific and technical infrastructures. We acknowledge J. Díaz from the CMCiB for his constant help at the BSL3 facility. We thank the contribution of E. Martró and V. Saludes from the Microbiology department of HUGTIP for their constant help to identify and sequence SARS-CoV-2 variants. The authors also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com) and Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real-time PCR system and an Eclipse Ts2RFL inverted research microscope., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants

  • Abancó, Ferran
  • Tarrés Freixas, Ferran
  • Lepore, Rosalba
  • Molina-Molina, Elisa
  • Franco, Eloi
  • Boreika, Rytis
  • Pradenas, Edwards
  • Raïch-Regué, Dàlia
  • Erkizia, Itziar
  • Clotet, Bonaventura
  • Valencia, Alfonso
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Trinité, Benjamin
The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has compromised the efficacy of many authorized monoclonal antibody products. This highlights the need for alternative strategies, especially for vulnerable populations such as immunocompromised individuals. Here, we optimized angiotensin-converting enzyme 2 (ACE2)-Fc fusion proteins by combining three engineering steps: in silico mutagenesis of the S protein binding interface to increase affinity, insertion of a flexible linker to improve protein stability and S protein accessibility, and generation of a tetrameric molecule to maximize avidity. Neutralizing activity was tested against a large panel of pre-Omicron and Omicron pseudoviruses and authentic viruses, including JN.1 and KP.2 variants. Optimized ACE2-Fc molecules demonstrated potent neutralizing activity, in the picomolar range, against all SARS-CoV-2 variants. Our molecules displayed similar potency but better resilience when compared to the monoclonal antibody Sipavibart. These findings support ACE2-Fc proteins as robust candidates for next-generation interventions against infection by an evolving SARS-CoV-2., We acknowledge Carmen Aguilar-Gurrieri from IrsiCaixa for her help on initial structural analysis and Jorge Díaz from CMCiB for his help at the BSL3 facility. We also acknowledge Carlo Carolis and Katrina Broadbent from CRG for their work on surface plasmon resonance. Benjamin Trinité was funded by Project DTS23009 from the Spanish “Instituto de Salud Carlos III (ISCIII)-Subdirección General de Evaluación” and “Fondo Europeo de Desarrollo Regional (FEDER).” Julià Blanco was partially funded by the crowdfunding initiative #joemcorono, GRIFOLS, and the Fundació Glòria Soler. Nuria Izquierdo-Useros is supported by the Spanish Ministry of Science and Innovation (grants PID2023-147498OB-I00 and 10.13039/501100011033, Spain), EU HORIZON-HLTH-2021CORONA-01 (grant 101046118, European Union), and by institutional funding from PharmaMar, GRIFOLS, HIPRA, and Amassence. Eloi Franco is supported by JDC2023-050389-I funded by MCIU/AEI/10.13039/501100011033 and FSE+. IrsiCaixa and IRTA are funded by the CERCA program/Generalitat de Catalunya. We acknowledge the funding from 2021-SGR-00651 project, 2021-SGR-01385, and 2021-SGR-00825 projects by the Generalitat de Catalunya., info:eu-repo/semantics/publishedVersion